文献速递头颈外科

T1-2 cN0 口咽癌患者行或不行择区性颈淋巴结清扫术的生存比较

Comparison of Survival of Patients With T1-2 cN0 Oropharyngeal Cancer Treated With or Without Elective Neck Dissection.
PubMed 文献 · Laryngoscope · 2021-11-19

基于监测、流行病学和最终结果数据库 2010-2015 年 845 例 T1-2 cN0 口咽癌患者的回顾性观察研究,采用 Cox 回归和倾向性评分匹配分析择区性颈淋巴结清扫术(END)的预后价值。HPV 阳性队列中 END 与更好的 3 年总生存独立相关(校正 HR 0.464,95%CI 0.235-0.916,P=0.027),HPV 阴性队列中 END 无预后价值(校正 HR 0.837,95%CI 0.535-1.310,P=0.435)。

要点

  • HPV 阳性 T1-2 cN0 口咽癌患者中,END 与更好的 3 年总生存独立相关(校正 HR 0.464)。
  • HPV 阴性 T1-2 cN0 口咽癌患者中,END 未显示总生存获益(校正 HR 0.837,95%CI 跨 1)。
  • HPV 阳性队列中 ≤65 岁及非扁桃体肿瘤患者更可能从 END 获益;HPV 阴性队列中扁桃体肿瘤患者可能获益。

核心结论

  • HPV 阳性 T1-2 cN0 口咽癌患者可从 END 获得总生存获益,尤其是年轻患者和非扁桃体肿瘤患者;HPV 阴性患者总体上不能从 END 获得总生存获益,但扁桃体肿瘤患者可能获益。

研究设计与样本

  • 观察性回顾性研究,纳入监测、流行病学和最终结果数据库 2010-2015 年诊断为 T1-2 cN0 口咽癌的 845 例患者。
  • 采用单变量和多变量 Cox 回归模型评估 END 的预后作用,并用倾向性评分匹配平衡 END 组与观察(OBS)组的协变量,在匹配队列中进行亚组分析,主要终点为总生存(OS)。

主要发现

  • HPV 阳性队列中,END 与更好的 3 年 OS 独立相关(校正 HR 0.464,95%CI 0.235-0.916,P=0.027)。
  • HPV 阴性队列中,END 无预后价值(校正 HR 0.837,95%CI 0.535-1.310,P=0.435)。
  • 亚组分析显示,HPV 阳性队列中 ≤65 岁患者和非扁桃体肿瘤患者更可能从 END 获益;HPV 阴性队列中扁桃体肿瘤患者可能从 END 获益。

临床怎么用

  • 作者认为 HPV 阳性 T1-2 cN0 口咽癌患者可从 END 获得总生存获益,尤其是年轻患者和非扁桃体肿瘤患者。
  • 作者认为 HPV 阴性 T1-2 cN0 口咽癌患者不能从 END 获得总生存获益,但扁桃体肿瘤患者可能获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: This study aimed to examine the prognostic value of elective neck dissection (END) in T1-2 clinical negative cervical lymph node (cN0 ) oropharyngeal cancer (OPC) patients. STUDY DESIGN: An observational retrospective study. METHODS: This retrospective study included 845 patients diagnosed with T1-2 cN0 OPC during 2010-2015 from Surveillance, Epidemiology, and End Results database. Univariable and multivariable Cox regression models were used to evaluate the prognostic roles of END. Furthermore, propensity score matching was used to balance the covariates between the END and observation (OBS) groups, and subgroup analyses were conducted in the matched cohorts. The primary endpoint was overall survival (OS). RESULTS: Our study showed that END was an independent prognostic factor associated with a better 3-year OS compared with OBS in human papillomavirus (HPV)-positive cohort (adjusted hazard ratio [HR], 0.464; 95% confidence interval [CI], 0.235-0.916; P = .027). However, we found no prognostic value of END in HPV-negative cohort (adjusted HR, 0.837; 95% CI, 0.535-1.310; P = .435). In the subgroup analyses, we found that younger patients (≤65 years old) and patients with nontonsillar tumors in HPV-positive cohort were more likely to benefit from END, while patients with tonsillar tumors in HPV-negative cohort may benefit from END. CONCLUSIONS: We found that patients with HPV-positive T1-2 cN0 OPC could benefit from END in terms of OS, especially younger patients and those with nontonsillar tumors. Patients with HPV-negative T1-2 cN0 OPC could not benefit from END in terms of OS, while those with tonsillar tumors may benefit from END. LEVEL OF EVIDENCE: 3 Laryngoscope, 132:1205-1212, 2022.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Zeng X, Peng L, Wen W, et al. Comparison of Survival of Patients With T1-2 cN0 Oropharyngeal Cancer Treated With or Without Elective Neck Dissection. Laryngoscope. 2021. PMID: 34797566. doi:10.1002/lary.29951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。